Oncodesign Precision Medicine Société anonyme (EPA:ALOPM)
France
· Delayed Price · Currency is EUR 0.586
-0.052 (-8.15%)
At close: Mar 6, 2026
Oncodesign Precision Medicine Société anonyme Company Description
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business.
The company’s product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson’s disease.
It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers, as well as on developing treatment for pancreatic and other cancers.
Oncodesign Precision Medicine Société anonyme was founded in 1995 and is based in Dijon, France.
Oncodesign Precision Medicine Société anonyme
| Country | France |
| Founded | 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Philippe Genne |
Contact Details
Address: 18 rue Jean Mazen Dijon, 21000 France | |
| Phone | 33 310 451 820 |
| Website | oncodesign.com |
Stock Details
| Ticker Symbol | ALOPM |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Philippe Genne Ph.D. | Chairman and Chief Executive Officer |
| Karine Lignel | Chief Operating Officer |
| Dr. Jan Hoflack Ph.D. | Chief Scientific Officer |
| Stephane Gerart | Chief Information Officer |
| Sylvie Fernandes Forster | Chief Legal Officer |